See more : ImmunoGen, Inc. (IMGN) Income Statement Analysis – Financial Results
Complete financial analysis of Advaxis, Inc. (ADXS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Advaxis, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Northumberland Bancorp (NUBC) Income Statement Analysis – Financial Results
- ARMOUR Residential REIT, Inc. (ARR) Income Statement Analysis – Financial Results
- Metalúrgica Riosulense S.A. (RSUL4.SA) Income Statement Analysis – Financial Results
- Fukuda Corporation (1899.T) Income Statement Analysis – Financial Results
- Change Healthcare Inc. (CHNGU) Income Statement Analysis – Financial Results
Advaxis, Inc. (ADXS)
About Advaxis, Inc.
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.00K | 250.00K | 3.24M | 253.00K | 2.33M | 6.06M | 12.03M | 3.99M | 0.00 | 1.00M | 0.00 | 0.00 | 0.00 | 508.48K | 29.69K | 65.74K | 154.20K | 431.96K | 552.87K | 116.41K | 0.00 | 0.00 |
| Cost of Revenue | 13.00K | 314.00K | 3.71M | 1.29M | 1.29M | 0.00 | 0.00 | 0.00 | 265.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -64.00K | -468.00K | -1.03M | 1.05M | 6.06M | 12.03M | 3.99M | -265.39K | 1.00M | 0.00 | 0.00 | 0.00 | 508.48K | 29.69K | 65.74K | 154.20K | 431.96K | 552.87K | 116.41K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | -25.60% | -14.44% | -407.91% | 44.94% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 24.08M | 7.61M | 10.56M | 15.61M | 14.42M | 56.97M | 71.90M | 48.77M | 24.22M | 8.69M | 5.62M | 6.65M | 8.08M | 4.90M | 2.32M | 2.48M | 2.13M | 1.40M | 1.18M | 125.94K | 0.00 | 0.00 |
| General & Administrative | 12.19M | 9.74M | 11.46M | 11.09M | 4.34M | 19.47M | 38.66M | 31.71M | 24.45M | 11.85M | 9.07M | 5.69M | 4.94M | 3.53M | 2.70M | 3.04M | 2.63M | 2.08M | 1.22M | 524.37K | 10.00K | 10.00K |
| Selling & Marketing | 0.00 | -473.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.19M | 8.42M | 11.46M | 11.09M | 4.34M | 19.47M | 38.66M | 31.71M | 24.45M | 11.85M | 9.07M | 5.69M | 4.94M | 3.53M | 2.70M | 3.04M | 2.63M | 2.08M | 1.22M | 524.37K | 10.00K | 10.00K |
| Other Expenses | 0.00 | 3.05M | -1.00K | -3.00K | 0.00 | -63.00K | -123.00 | -201.00 | -35.08K | 6.24K | -3.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 36.27M | 16.03M | 22.03M | 26.70M | 18.76M | 76.44M | 110.56M | 80.49M | 48.67M | 20.54M | 14.69M | 12.33M | 13.02M | 8.43M | 5.02M | 5.52M | 4.76M | 3.48M | 2.40M | 650.31K | 10.00K | 10.00K |
| Cost & Expenses | 36.28M | 16.34M | 22.03M | 26.70M | 20.05M | 76.44M | 110.56M | 80.49M | 48.67M | 20.54M | 14.69M | 12.33M | 13.02M | 8.43M | 5.02M | 5.52M | 4.76M | 3.48M | 2.40M | 650.31K | 10.00K | 10.00K |
| Interest Income | 28.00K | 74.00K | 5.00K | 110.00K | 225.00K | 577.00K | 669.76K | 331.53K | 114.22K | 36.31K | 5.40K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 15.75M | 0.00 | 260.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.25K | 987.75K | 4.54M | 4.70M | 3.81M | 851.01K | 0.00 | 0.00 | 0.00 | 36.67K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 369.00K | 314.00K | 990.00K | 1.98M | 1.48M | 1.50M | 1.12M | 536.19K | 265.39K | 203.30K | 178.64K | 161.78K | 160.69K | 138.95K | 111.16K | 197.35K | 263.78K | 144.39K | 41.10K | 15.82K | 0.00 | 0.00 |
| EBITDA | -35.87M | -15.78M | -18.77M | -24.39M | -17.56M | -72.28M | -97.43M | -76.03M | -48.36M | -19.29M | -18.04M | -12.17M | -13.78M | -7.79M | -4.88M | -5.30M | -7.09M | -193.70K | -1.80M | -518.14K | -10.00K | -10.00K |
| EBITDA Ratio | -275,915.38% | -6,310.40% | -579.20% | -9,641.90% | -752.40% | -1,192.12% | -809.80% | -1,903.07% | 0.00% | -1,929.27% | 0.00% | 0.00% | 0.00% | -1,531.44% | -16,422.51% | -8,064.18% | -4,601.10% | -44.84% | -325.82% | -445.12% | 0.00% | 0.00% |
| Operating Income | -36.27M | -16.09M | -18.79M | -26.45M | -17.71M | -70.38M | -98.53M | -76.49M | -48.67M | -19.54M | -14.69M | -12.33M | -13.02M | -7.93M | -4.99M | -5.45M | -4.60M | -3.05M | -1.84M | -533.90K | -10.00K | -10.00K |
| Operating Income Ratio | -278,969.23% | -6,436.00% | -579.81% | -10,454.15% | -758.83% | -1,160.79% | -818.95% | -1,914.77% | 0.00% | -1,953.86% | 0.00% | 0.00% | 0.00% | -1,558.76% | -16,796.90% | -8,293.45% | -2,985.06% | -705.91% | -333.25% | -458.66% | 0.00% | 0.00% |
| Total Other Income/Expenses | -16.72M | 1.78M | 974.00K | 30.00K | 225.00K | 3.91M | 20.03K | 68.85K | -84.03K | 625.33K | -5.03M | 4.45M | 10.15M | 649.70K | 5.85M | 46.63K | 2.76M | -2.71M | 36.67K | 57.00 | 0.00 | 0.00 |
| Income Before Tax | -51.98M | -14.31M | -17.81M | -26.42M | -17.49M | -66.47M | -97.84M | -76.09M | -48.64M | -18.88M | -20.71M | -12.42M | -8.50M | -11.09M | 7.22K | -5.41M | -1.85M | -5.76M | -1.81M | -533.85K | -10.00K | -10.00K |
| Income Before Tax Ratio | -399,876.92% | -5,723.60% | -549.75% | -10,442.29% | -749.19% | -1,096.24% | -813.21% | -1,904.75% | 0.00% | -1,888.22% | 0.00% | 0.00% | 0.00% | -2,181.24% | 24.32% | -8,222.52% | -1,197.96% | -1,333.56% | -326.62% | -458.61% | 0.00% | 0.00% |
| Income Tax Expense | -3.91M | 50.00K | 50.00K | 50.00K | 306.00K | 50.00K | -4.40M | -2.54M | -1.61M | -2.36M | -725.19K | -346.79K | -379.47K | -278.98K | -922.02K | -35.37K | -2.15M | 3.15M | -36.67K | 4.17K | 0.00 | 0.00 |
| Net Income | -48.07M | -14.36M | -17.86M | -26.47M | -17.79M | -66.52M | -93.44M | -73.56M | -47.03M | -16.53M | -19.99M | -12.07M | -8.12M | -10.81M | 929.24K | -5.42M | -2.45M | -6.20M | -1.81M | -538.08K | -10.00K | -10.00K |
| Net Income Ratio | -369,784.62% | -5,743.60% | -551.30% | -10,462.06% | -762.30% | -1,097.06% | -776.62% | -1,841.27% | 0.00% | -1,652.53% | 0.00% | 0.00% | 0.00% | -2,126.37% | 3,129.82% | -8,239.65% | -1,591.72% | -1,434.79% | -326.62% | -462.24% | 0.00% | 0.00% |
| EPS | -7.99 | -7.90 | -11.07 | -34.71 | -93.60 | -19.37 | -34.58 | -31.17 | -25.17 | -14.49 | -59.83 | -70.60 | -68.27 | -134.35 | 1.21K | -90.76 | -98.58 | -300.70 | -94.62 | -9.02 | 0.00 | 0.00 |
| EPS Diluted | -7.99 | -7.90 | -11.07 | -34.71 | -93.60 | -19.37 | -34.58 | -31.17 | -25.17 | -14.49 | -59.83 | -70.60 | -68.27 | -134.35 | 1.21K | -90.76 | -98.58 | -300.70 | -94.62 | -9.02 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 6.02M | 1.82M | 1.61M | 762.55K | 190.10K | 3.43M | 2.70M | 2.36M | 1.87M | 1.14M | 334.08K | 170.96K | 118.88K | 80.48K | 61.60K | 59.68K | 24.90K | 20.61K | 19.08K | 59.68K | 145.64M | 145.64M |
| Weighted Avg Shares Out (Dil) | 6.02M | 1.82M | 1.61M | 762.55K | 190.10K | 3.43M | 2.70M | 2.36M | 1.87M | 1.14M | 334.08K | 170.96K | 118.88K | 80.48K | 61.60K | 59.68K | 24.90K | 20.61K | 19.08K | 59.68K | 145.64M | 145.64M |
Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under...
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM).
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
AL102 1.2 mg once daily treatment achieved Overall Response Rate of 83% in the evaluable population AL102 1.2 mg once daily treatment resulted in 88% reduction in tumor volume and 85% reduction in T2W signal intensity REHOVOT, Israel and MONMOUTH...
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the closing of its merger with Biosight, Ltd. (“Biosight”), pursuant to which Ayala acquired Biosight. The combined...
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Definitive merger agreement with Biosight, expected to close near end of...
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a publicly-traded clinical-stage oncology company, today announced that it will present posters on its gamma secretase inhibitors AL102 and AL101 at the European Society...
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
Combined company to operate as Ayala Pharmaceuticals, Inc. Merger to add a clinical stage oncology asset to Ayala's portfolio with data anticipated in the first half of 2024 REHOVOT and TEL AVIV, Israel and MONMOUTH JUNCTION, N.J., July 27, 2023...
Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA ® (pembrolizumab)
OTC Markets Group Welcomes Advaxis, Inc. to OTCQX
NEW YORK, Dec. 23, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for over 11,000 U.S. and global securities, today announced Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company, has qualified to trade on the OTCQX® Best...
3 Hot Penny Stocks That Retail Traders Are Watching Right Now
Why retail traders are watching these penny stocks right now The post 3 Hot Penny Stocks That Retail Traders Are Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Source: https://incomestatements.info
Category: Stock Reports